novel urinary and plasma biomarkers NGAL, KIM-1, TIMP-2, IGFBP7 demonstrate superior efficacy compared to creatinine in enabling very early identification of high-risk patients ahead of AKI development as well as accurate prediction of AKI severity, need for RRT and mortality risk [91]. This evidence concerns the gene LCN2 and acute kidney injury.